Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective

被引:0
|
作者
Earle, Kylie [1 ]
Williams, Scott [2 ]
机构
[1] Pfizer Australia, Access & Publ Affairs, Australia 38-42 Wharf Rd, Sydney, NSW 2114, Australia
[2] Pfizer Australia, Vaccines, Sydney, NSW, Australia
来源
PNEUMONIA | 2016年 / 8卷
关键词
Pneumonia; Pneumococcal disease; Burden of disease; Adults; Streptococcus pneumoniae;
D O I
10.1186/s41479-016-0008-8
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The burden of pneumococcal disease in adults aged 65 years and older in Australia is not well defined. This retrospective cross-sectional study calculated rates for pneumococcal pneumonia using data from the Australian Institute of Health and Welfare and from the Bettering Evaluation and Care of Health program. Methods: Invasive pneumococcal disease (IPD) incidence was calculated using National Notifiable Diseases Surveillance System data. Population estimates and pneumonia mortality data were from the Australian Bureau of Statistics. Medical costs were derived from Australian Refined Diagnosis Related Groups and the literature. Clinical and economic burden of pneumococcal pneumonia hospitalisations and general practitioner (GP) visits were described and compared with IPD. Results: For adults aged >= 65 years, pneumococcal pneumonia hospitalisation incidence was 274 per 100,000 population in 2011-2012. From 2004 to 2012, a mean of 2235 pneumonia hospitalisation deaths were recorded, corresponding to a case fatality rate of 6.1 %. GP visits accounted for the largest portion of healthcare encounters, with an annual average of 455 pneumococcal pneumonia GP visits per 100,000 population from 2008 to 2013. In 2012, IPD incidence was 19 per 100,000 population. The estimated annual costs of treating pneumococcal pneumonia hospitalisations and GP visits were A$55,722,136 and A$1,604,189, respectively. Estimated costs for IPD were A$1,172,986. Conclusions: The healthcare and economic burden of pneumococcal disease in adults aged >= 65 years in Australia is substantial, with the incidence of pneumococcal pneumonia hospitalisation nearly 15-fold higher than for IPD. Despite this, it remains less recognised than other infectious diseases such as influenza.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective
    Kylie Earle
    Scott Williams
    Pneumonia, 8 (1)
  • [2] Clinical and Economic Burden of Pneumococcal Disease in US Adults Aged 50 Years and Older.
    Weycker, D.
    Sato, R.
    Strutton, D.
    Jackson, L.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2010, 58 : 149 - 149
  • [3] Cost-Effectiveness of Pneumococcal Vaccines for Adults Aged 65 Years and Older in Argentina
    Giglio, Norberto D.
    Castellano, Vanesa E.
    Mizrahi, Patricia
    Micone, Paula, V
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 76 - 81
  • [5] Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older
    CollIgnon, Peter J.
    MEDICAL JOURNAL OF AUSTRALIA, 2014, 201 (04) : 199 - 200
  • [6] Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older
    Menzies, Robert I.
    Jayasinghe, Sanjay H.
    Krause, Vicki L.
    Chiu, Clayton K.
    McIntyre, Peter B.
    MEDICAL JOURNAL OF AUSTRALIA, 2014, 200 (02) : 112 - 115
  • [7] Economic Burden of Pneumococcal Disease in Individuals Aged 15 Years and Older in the Liguria Region of Italy
    Astengo, Matteo
    Paganino, Chiara
    Amicizia, Daniela
    Trucchi, Cecilia
    Tassinari, Federico
    Sticchi, Camilla
    Sticchi, Laura
    Orsi, Andrea
    Icardi, Giancarlo
    Piazza, Maria Francesca
    Di Silverio, Bruno
    Deb, Arijita
    Senese, Francesca
    Prandi, Gian Marco
    Ansaldi, Filippo
    VACCINES, 2021, 9 (12)
  • [8] Retirement patterns of Australian doctors aged 65 years and older
    Joyce, Catherine M.
    Wang, Wei C.
    McDonald, Hayley M.
    AUSTRALIAN HEALTH REVIEW, 2015, 39 (05) : 582 - 587
  • [9] Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany
    Deb, Arijita
    Podmore, Belene
    Barnett, Rosemarie
    Beier, Dominik
    Galetzka, Wolfgang
    Qizilbash, Nawab
    Haeckl, Dennis
    Mihm, Sarah
    Johnson, Kelly D.
    Weiss, Thomas
    EPIDEMIOLOGY & INFECTION, 2022, 150
  • [10] Recommendation for conjugate pneumococcal and pneumococcal polysaccharide vaccines in adults older than 65 years
    Niemi, Sarah A.
    Foster, Stephan L.
    Hayney, Mary S.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2015, 55 (02) : 212 - 215